MEDICAL RESEARCH
Untitled Page
Studies show Irvine's Cortex therapy slows memory loss
AMPAKINE treatment may bring favorable results to patients suffering from Huntington's disease.
By Kristen SchottPublished: March 06, 2009 02:33 PM
Irvine-based Cortex Pharmaceuticals' AMPAKINE molecules could be beneficial during the treatment of memory loss in Huntington's disease, according to a recent study from UC Irvine professor Gary Lynch, who is also a scientific founder of the company.
The tests were performed in mice carrying the same genetic mutation found in humans that causes Huntington's, a hereditary brain disease in which specific brain cells die. It is characterized by the progressive deterioration of cognitive processes and memory.
The results demonstrated that treating the mice with CX929, a high-impact AMPAKINE – molecules that increase the strength of signals at connections between brain cells – produced increases in the brain's chemical processes for creating and storing memories.
PAGE TWO
Related headlines
Irvine-based Masimo's product revenue jumps 30 percent in 2008
St. Joseph's Hospital of Orange gets blue light
UC Irvine researchers study brain link to autism
"OC METRO Minute," March 5: Tissue engineering, regenerative medicine markets expected to grow by 2013
|
||||
|
The tests were performed in mice carrying the same genetic mutation found in humans that causes Huntington's, a hereditary brain disease in which specific brain cells die. It is characterized by the progressive deterioration of cognitive processes and memory. The results demonstrated that treating the mice with CX929, a high-impact AMPAKINE – molecules that increase the strength of signals at connections between brain cells – produced increases in the brain's chemical processes for creating and storing memories. PAGE TWO Related headlines Irvine-based Masimo's product revenue jumps 30 percent in 2008 St. Joseph's Hospital of Orange gets blue light UC Irvine researchers study brain link to autism "OC METRO Minute," March 5: Tissue engineering, regenerative medicine markets expected to grow by 2013 |
||||
